Global Uveal Melanoma Therapeutics Market: Market Size, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024
Global Uveal Melanoma Therapeutics Market: Market Size, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024
(EMAILWIRE.COM, May 26, 2018 ) Global Uveal Melanoma Therapeutics Market: Market Size, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024
Global Uveal Melanoma Therapeutics Market: By Disease Type (Choroidal Melanomas, Iris Melanomas, and Ciliary Body Melanomas), By Treatment Type (Chemotherapy, Immunotherapy, and Targeted Therapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography - Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024
Global uveal melanoma therapeutics market was valued at US$ XX Mn in 2017 and expected to grow at XX% Compound Annual Growth Rate (CAGR) from 2018 to 2024
Market Outline: Uveal Melanoma Therapeutics Market
Uveal melanoma is a disease in which malignant (cancer) cells form in the tissues of the eye. The tumors arise from the melanocytes that reside within the uvea giving color to the eye. Uveal melanoma begins between the three layers of the wall of the eye. The first layer (outer layer) includes sclera and the cornea at the front of the eye. The inner layer has a retina, that senses light and send images. The middle layer is the layer in which the melanoma forms. This layer is called as uvea.
Increase in the prevalence of uveal melanoma is driving the growth of the market. The rising awareness among the people regarding the disease among healthcare fraternity is anticipated to drive the growth of the uveal melanoma therapeutics market. However, the higher cost of the therapy and reimbursement policies are may constrain the growth of the market.
Free sample of this report is available upon request @https://www.precisionbusinessinsights.com/market-reports/uveal-melanoma-therapeutics-market/#ulp-4H8Z4LpNMLEuOnnx
Market Scope: Uveal Melanoma Therapeutics Market
Uveal melanoma therapeutics market is segmented based on the disease type, treatment type, and distribution channel.
Based on the disease type, the market is segmented into the following:
• Choroidal Melanomas
o Small Melanomas
o Medium-sized Melanomas
o Large Melanomas
• Iris melanomas
• Ciliary Body Melanomas
Based on the treatment type, the market is segmented into the following:
• Chemotherapy
o Methotrexate
o Others
• Immunotherapy Drugs
o Pembrolizumab
o Ipilimumab
o Others
• Targeted Drugs
Based on the distribution channel, the market is segmented into the following:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Free TOC of this report is available upon request @https://www.precisionbusinessinsights.com/market-reports/uveal-melanoma-therapeutics-market/#ulp-c654SbFYO64MsOhu
Regional Analysis: Uveal Melanoma Therapeutics Market
Geographically, global uveal melanoma therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America uveal melanoma therapeutics market is driven by increase in the prevalence of the eye related disorders. The growing patient population with uveal melanoma disorder expected fuel the market growth in the region. According to the American Cancer Society, about nine of 10 melanomas of the eye develop in the choroid. It also states that 2,730 new cases were detected in 2014 of uveal melanoma in the U.S.
Competition Assessment: Uveal Melanoma Therapeutics Market
Some of the players in the global uveal melanoma therapeutics market include:
• Eli Lilly & Co. (U.S)
• Novartis AG (Switzerland)
• AstraZeneca plc (UK)
• Pfizer, Inc. (U.S)
• Merck (U.S)
• Roche (Switzerland)
• Amgen (U.S)
• Bayer (Germany)
• Spectrum Pharmaceuticals, Inc. (U.S)
Ask Analyst for Full Information about this report @https://www.precisionbusinessinsights.com/market-reports/uveal-melanoma-therapeutics-market/#ulp-14mlyhjMGhVjZqa3
Notable Market Developments: Uveal Melanoma Therapeutics Market
Bristol-Myers Squibb and National Cancer Institute (NCI) completed the phase II study of Nivolumab in combination with Ipilimumab for Uveal Melanoma
Get access to full summary @https://www.precisionbusinessinsights.com/market-reports/uveal-melanoma-therapeutics-market/
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US):+1-866-598-1553
Website @https://www.precisionbusinessinsights.com
Global Uveal Melanoma Therapeutics Market: By Disease Type (Choroidal Melanomas, Iris Melanomas, and Ciliary Body Melanomas), By Treatment Type (Chemotherapy, Immunotherapy, and Targeted Therapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography - Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024
Global uveal melanoma therapeutics market was valued at US$ XX Mn in 2017 and expected to grow at XX% Compound Annual Growth Rate (CAGR) from 2018 to 2024
Market Outline: Uveal Melanoma Therapeutics Market
Uveal melanoma is a disease in which malignant (cancer) cells form in the tissues of the eye. The tumors arise from the melanocytes that reside within the uvea giving color to the eye. Uveal melanoma begins between the three layers of the wall of the eye. The first layer (outer layer) includes sclera and the cornea at the front of the eye. The inner layer has a retina, that senses light and send images. The middle layer is the layer in which the melanoma forms. This layer is called as uvea.
Increase in the prevalence of uveal melanoma is driving the growth of the market. The rising awareness among the people regarding the disease among healthcare fraternity is anticipated to drive the growth of the uveal melanoma therapeutics market. However, the higher cost of the therapy and reimbursement policies are may constrain the growth of the market.
Free sample of this report is available upon request @https://www.precisionbusinessinsights.com/market-reports/uveal-melanoma-therapeutics-market/#ulp-4H8Z4LpNMLEuOnnx
Market Scope: Uveal Melanoma Therapeutics Market
Uveal melanoma therapeutics market is segmented based on the disease type, treatment type, and distribution channel.
Based on the disease type, the market is segmented into the following:
• Choroidal Melanomas
o Small Melanomas
o Medium-sized Melanomas
o Large Melanomas
• Iris melanomas
• Ciliary Body Melanomas
Based on the treatment type, the market is segmented into the following:
• Chemotherapy
o Methotrexate
o Others
• Immunotherapy Drugs
o Pembrolizumab
o Ipilimumab
o Others
• Targeted Drugs
Based on the distribution channel, the market is segmented into the following:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Free TOC of this report is available upon request @https://www.precisionbusinessinsights.com/market-reports/uveal-melanoma-therapeutics-market/#ulp-c654SbFYO64MsOhu
Regional Analysis: Uveal Melanoma Therapeutics Market
Geographically, global uveal melanoma therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America uveal melanoma therapeutics market is driven by increase in the prevalence of the eye related disorders. The growing patient population with uveal melanoma disorder expected fuel the market growth in the region. According to the American Cancer Society, about nine of 10 melanomas of the eye develop in the choroid. It also states that 2,730 new cases were detected in 2014 of uveal melanoma in the U.S.
Competition Assessment: Uveal Melanoma Therapeutics Market
Some of the players in the global uveal melanoma therapeutics market include:
• Eli Lilly & Co. (U.S)
• Novartis AG (Switzerland)
• AstraZeneca plc (UK)
• Pfizer, Inc. (U.S)
• Merck (U.S)
• Roche (Switzerland)
• Amgen (U.S)
• Bayer (Germany)
• Spectrum Pharmaceuticals, Inc. (U.S)
Ask Analyst for Full Information about this report @https://www.precisionbusinessinsights.com/market-reports/uveal-melanoma-therapeutics-market/#ulp-14mlyhjMGhVjZqa3
Notable Market Developments: Uveal Melanoma Therapeutics Market
Bristol-Myers Squibb and National Cancer Institute (NCI) completed the phase II study of Nivolumab in combination with Ipilimumab for Uveal Melanoma
Get access to full summary @https://www.precisionbusinessinsights.com/market-reports/uveal-melanoma-therapeutics-market/
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US):+1-866-598-1553
Website @https://www.precisionbusinessinsights.com
Contact Information:
Precision Business Insights
Satya Satya
Tel: 18665981553
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Precision Business Insights
Satya Satya
Tel: 18665981553
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results